Home
Aktuelles
Wir über uns
Tumorarten
Anfahrt
Kontakt
Impressum
Aktuelles
Wir über uns
| Ärzte Team Diagnostik Therapie Studien Praxis Porz Praxis Kalk Kooperationen Zertifikate |
Anfahrt
Kontakt
Impressum
Publikationsliste – Achim Rothe
- Rothe, A.*, Jachimowicz, R.*, Borchmann*, S. (* These authors contributed equally), Madlener, M., Keßler, J., Reiners, K.S., Hansen, H.P., Ulrich, R., Chatterjee, C., Borchmann. P., Yazaki. P., Koslowsky, T.C., Engert, A., Heukamp, L., Hallek, M., Pogge von Strandmann, E., The bispecific immunoligand ULBP2-aCEA re-directs Natural killer cells to tumor cells and reveals potent anti-tumor activity against colon carcinoma. Int J Cancer, 2013, accepted.
- Kahraman, D. *, Theurich, S. *, Rothe, A. * (*These authors contributed equally), Kuhnert, G., Sasse, S., Scheid, C., Dietlein. M., von Bergwelt-Baildon, M., Kobe, K., FDG-PET/CT to monitor treatment response to Brentuximab Vedotin in relapsed/refractory Hodgkin Lymphoma. Leuk Lymphoma, 2013, accepted.
- Bossaller, L and Rothe, A. Monoclonal antibody treatments for rheumatoid arthritis. Expert Opin Biol Ther. 2013, in press.
- Theurich, S., Wennhold, K., Holtick, U., Wedemeyer, I., Kobe, K., Kahraman, K., Shimabukuro-Vornhagen, A., Hübel, K., Rothe, A., Chemnitz, J., Hallek, M., Scheid, C., von Bergwelt-Baildon, M. CD30-targeted therapy combined with DLI in a patient with lymphoblastic T-cell PTLD: induction of clinical remission and cellular immunity. Transplantation, 2013, in press.
- Sasse*, S., and Rothe*, A. (* Both first authors contributed equally), Goergen, H., Eichenauer, D.A., Lohri, A., Jäger, U., Bangard, C., Böll, B., von Bergwelt Baildon, M., Theurich, S., Borchmann, P., Engert, A., Brentuximab vedotin (SGN-35) in patients with transplant-naive relapsed/refractory Hodgkin lymphoma. Leuk Lymphoma. 2013 Mar 27.
- 6. Reiners, K.S., Kessler, J., Sauer, M., Rothe, A., Hansen, H., Reusch1, U., Hucke, C., Köhl, U., Dürkop, H., Engert, A., Pogge von Strandmann, E., Rescue of impaired NK cell activity in hodgkin lymphoma with bispecific antibodies in vitro and in patients. Mol Ther. 2013 Apr;21(4):895-903. 2013.14. Epub 2013 Mar 5.
- Theurich, S., Fischmann, H., Chakupurakal, G., Shimabukuro-Vornhagen, A., Chemnitz, J., Holtick, U., Rothe, A., Scheid, C., Hallek, M., Skoetz, N., von Bergwelt-Baildon, M. Anti-thymocyte globulins for post-transplant graft-versus-host disease prophylaxis – a systematic review and meta-analysis. Crit Rev Oncol Hematol. 2013 Apr 2. S1040-8428. 2013.03.009.
- Böll, B., Goergen, H., Fuchs, M., Pluetschow, A., Eich, H.T., Lohri, A., Weidmann, E., Fritsch, G., Leithäuser, M., Greil, R., Scherpe, A., Schmalz, O., Eichenauer, D.A., von Tresckow, B., Rothe, A., Diehl, V., Engert, A., Borchmann, P. ABVD in Elderly Early Stage Hodgkin Lymphoma Patients treated within the German Hodgkin Study Group (GHSG) HD10 and HD11 Trials. J Clin Oncol. 2013 Apr 20;31(12):1522-9. Epub 2013 Mar 18.
- Rothe, A., Sasse, S., Eichenauer, D.A., Bangard, C., Borchmann, P., and Engert, A., Brentuximab vedotin (SGN-35) for relapsed CD30-positive hematologic malignancies. Blood. 2012 Aug 16;120(7):1470-2. Epub 2012 Jul 11.
- Shimabukuro-Vornhagen, A., Draube, A., Liebig, T.M.,Popov, A., Rothe, A., von Bergwelt-Baildon, M.S. The properties of human CD40-activated B cells as antigen-presenting cells are not affected by PGE2, Oncol Rep. 2013 Mar;29(3):1061-5. Epub 2012 Dec 28. << Zurück Weiter >>
MVZ West GmbH
DatenschutzerklärungStandort Köln-Kalk und Standort Köln-Porz |
Buchforststr. 14 /
51103 Köln-Kalk Urbacher Weg 19 / 51149 Köln-Porz |
Tel.: 0221/872047 Tel.: 02203/699400 |